All In Biotech

Investigational drug · Phase 3

HSK39297

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH).

Phase 3

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

2 still active

All registered trials

11

Any phase or sponsor naming "HSK39297"

First trial start

2024

Jul 17, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HSK39297", any sponsor or status.

Conditions studied

As listed on its trial records.

  • IgA Nephropathy (IgAN)
  • Paroxysmal Nocturnal Hemoglobinuria
  • Paroxysmal Nocturnal Haemoglobinuria (PNH)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • PNH

Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "HSK39297" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for IgA Nephropathy (IgAN)

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • MY008211APhase 35 trials

    Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)

  • JADE101Phase 32 trials

    Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy

  • SC0062Phase 31 trial

    Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)

  • HSK39297 200mgQDPhase 23 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)

  • HSK39297 300mgQDPhase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)

  • SGB-9768Phase 22 trials

    Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy

  • SLN12140Phase 22 trials

    Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.